Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · May 16, 2024

NECTIN4 Amplification as a Genomic Biomarker to Predict Enfortumab Vedotin Response in Metastatic Urothelial Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer
J. Clin. Oncol 2024 Apr 24;[EPub Ahead of Print], N Klümper, NK Tran, S Zschäbitz, O Hahn, T Büttner, F Roghmann, C Bolenz, F Zengerling, C Schwab, D Nagy, M Toma, G Kristiansen, H Heers, P Ivanyi, G Niegisch, CM Grunewald, C Darr, A Farid, K Schlack, M Abbas, C Aydogdu, J Casuscelli, T Mokry, M Mayr, D Niedersüß-Beke, S Rausch, D Dietrich, J Saal, J Ellinger, M Ritter, A Alajati, C Kuppe, J Meeks, FE Vera Badillo, JA Nakauma-González, J Boormans, K Junker, A Hartmann, V Grünwald, M Hölzel, M Eckstein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading